Ledipasvir/ sofosbuvir – rapid development of knowledge reduces treatment time
Petr Husa1
+ Affiliation
Summary
Keywords
HCV, chronic hepatitis C, ledipasvir, ribavirin, sofosbuvir, hepatitis C virusTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61 (2): 373–395. doi: 10.1016/j.jhep.2014.05.001.
2. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63 (1): 199–236. doi: 10.1016/j.jhep.2015.03.025.
3. American Association for the Study of Liver Disease. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Available from: www.hcvguidelines.org.
4. Souhrnu údajů o přípravku Harvoni [on- line]. Dostupné z: http: //www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_ –_Product_Information/human/003850/ WC500177995.pdf.
5. Bourlière M, Sulkowski MS, Omata M et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 2014; 60: 239A.
6. Bourlière M, Bronowicki JP, de Ledinghen V et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15 (4): 397–404. doi: 10.1016/S1473-3099 (15) 70050-2.
7. Flamm SL, Everson GT, Charlton M et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenrter study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Hepatology 2014; 60: 320A.
8. Reddy RK, Everson GT, Flamm SL et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014; 60: 200A–201A.
9. Gane E, Manns MP, Forns X et al. 365 Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR2 trial. Gastroenterology 2015; 148 (4): S-978. doi: 10.1016/S0016-5085 (15) 33342-4.